ACROSS a large safety analysis, CFTR modulators showed no increase in neuropsychiatric events among patients with cystic fibrosis. The study combined clinical trial and real-world data covering more than 250,000 patient-years of treatment experience with laboratory, animal, and human genetic analyses. It was prompted by reports of new or worsening symptoms, including depression, anxiety, sleep disturbances, and difficulty concentrating, in a minority of patients receiving these therapies.
Psychiatric Event Rates With CFTR Modulators
Across 72 Phase II and Phase III trials, the pooled rate of neuropsychiatric events was 7.4 per 100 person-years with CFTR modulators and 9.5 per 100 person-years with placebo. Serious events and events leading to treatment discontinuation were infrequent and occurred at similar rates. The analysis included five regimens, among them elexacaftor/tezacaftor/ivacaftor and vanzacaftor/tezacaftor/deutivacaftor.
Registry data showed no change in the prevalence of depression or anxiety diagnoses after patients began elexacaftor/tezacaftor/ivacaftor. In a review of 12 studies that measured depression scores after treatment initiation, eight reported no change, three reported improvement, and one reported mixed results depending on the assessment tool. Of 11 studies that evaluated anxiety, nine found no change and two reported improvement.
Laboratory and Genetic Findings
Laboratory testing identified no relevant off-target binding at clinically relevant unbound drug concentrations. Rat studies found no measurable behavioral changes on the tests used. In genetic data from approximately 1 million people, investigators found no association between the CFTR variants they studied and any of 23 neuropsychiatric conditions.
What the Findings Mean for Individual Patients
The clinical trials and registries did not systematically collect detailed neuropsychiatric assessments, which limited their ability to detect rare or subtle effects. Patients with a history of mental health conditions may also have been underrepresented in the trials. The population-level findings leave open the possibility of rare effects in individual patients who report symptoms after starting treatment. The pharmaceutical sponsor participated in study design, data analysis, and interpretation.




